Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study

NCT02052193 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

8

Enrollment

OTHER

Sponsor class

Stopped Second cohort not opened because Simon-Two\_Step model failed

Conditions

Metastatic Melanoma (Carrying BRAF V600 Mutation)

Interventions

DRUG: Dabrafenib
DRUG: Vemurafenib

Sponsor

University Hospital Tuebingen